These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
279 related items for PubMed ID: 16125868
1. Asymmetric dimethylarginine: a molecule responsible for the coexistence of insulin resistance and atherosclerosis via dual nitric oxide synthase inhibition. Zsuga J, Gesztelyi R, Török J, Kéki S, Bereczki D. Med Hypotheses; 2005; 65(6):1091-8. PubMed ID: 16125868 [Abstract] [Full Text] [Related]
6. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. De Gennaro Colonna V, Bianchi M, Pascale V, Ferrario P, Morelli F, Pascale W, Tomasoni L, Turiel M. Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216 [Abstract] [Full Text] [Related]
7. Gene transfer of dimethylarginine dimethylaminohydrolase-2 improves the impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells induced by lysophosphatidylcholine. Feng M, Liu L, Guo Z, Xiong Y. Eur J Pharmacol; 2008 Apr 14; 584(1):49-56. PubMed ID: 18342305 [Abstract] [Full Text] [Related]
15. ADMA: its role in vascular disease. Cooke JP. Vasc Med; 2005 Jul 14; 10 Suppl 1():S11-7. PubMed ID: 16444864 [Abstract] [Full Text] [Related]
16. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, Tsujimoto T, Toyohira Y, Hayashida Y, Sasaguri Y, Ueta Y, Nakashima Y, Yanagihara N. Arterioscler Thromb Vasc Biol; 2004 Sep 14; 24(9):1682-8. PubMed ID: 15217805 [Abstract] [Full Text] [Related]
17. Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH. Pluta RM. Neurol Res; 2006 Oct 14; 28(7):730-7. PubMed ID: 17164036 [Abstract] [Full Text] [Related]
18. Packed red blood cells are an abundant and proximate potential source of nitric oxide synthase inhibition. Zwemer CF, Davenport RD, Gomez-Espina J, Blanco-Gonzalez E, Whitesall SE, D'Alecy LG. PLoS One; 2015 Oct 14; 10(3):e0119991. PubMed ID: 25793525 [Abstract] [Full Text] [Related]
19. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, Hoeper MM, Haller H, Fliser D. Circulation; 2004 Jan 20; 109(2):172-7. PubMed ID: 14662708 [Abstract] [Full Text] [Related]
20. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function. Richir MC, Bouwman RH, Teerlink T, Siroen MP, de Vries TP, van Leeuwen PA. JPEN J Parenter Enteral Nutr; 2008 Jan 20; 32(6):613-21. PubMed ID: 18974239 [Abstract] [Full Text] [Related] Page: [Next] [New Search]